IP Library › Granted Patent US 12697393
Granted Patent B2
US 12697393 · App. 19/554,962 · Granted Aug 4, 2026

Oral biodelivery platform

Inventors: Cory Henderson (Oakland, CA); Kwangchul Kwon (Oakland, CA)
Assignee: BioDrive, Inc.
A61K47/64A61K9/0019A61K31/198A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697393
App. No.
19/554,962
Granted
Aug 4, 2026
Kind
B2
Abstract

The present disclosure provides a biodelivery platform for the oral administration of molecular cargo.

Claims (19)

1 . A composition comprising: Saccharomyces cerevisiae S288C EV1-Peptide, wherein the Saccharomyces cerevisiae S288C EV1-Peptide comprises EV1-Peptide comprising SEQ ID NO: 6.

2 . The composition of claim 1 , wherein the Saccharomyces cerevisiae S288C EV1-Peptide comprises SEQ ID NO: 1.

3 . The composition of claim 1 , wherein the Saccharomyces cerevisiae S288C EV1-Peptide is encapsulated.

4 . The composition of claim 1 , wherein the Saccharomyces cerevisiae S288C EV1-Peptide is encapsulated in a capsule and present in a dosage form comprising from about 50 mg to about 1000 mg of Saccharomyces cerevisiae S288C EV1-Peptide.

5 . The composition of claim 1 , wherein the Saccharomyces cerevisiae S288C EV1-Peptide is encapsulated in a capsule and present in a dosage form comprising from about 100 mg to about 600 mg of Saccharomyces cerevisiae S288C EV1-Peptide.

6 . The composition of claim 1 , wherein the Saccharomyces cerevisiae S288C EV1-Peptide is encapsulated in a capsule and present in a dosage form comprising about 300 mg of Saccharomyces cerevisiae S288C EV1-Peptide.

7 . The composition of claim 5 , wherein the dosage form comprises from about 100 mcg to about 5000 mcg EV1-peptide.

8 . The composition of claim 5 , wherein the dosage form comprises about 500 mcg to about 3000 mcg EV1-peptide.

9 . The composition of claim 6 , wherein the dosage form comprises about 900 mcg EV1-peptide.

10 . The composition of claim 6 , wherein the dosage form comprises about 1800 mcg EV1-peptide.

11 . The composition of claim 1 , wherein the Saccharomyces cerevisiae S288C EV1-Peptide is encapsulated in a vegan capsule.

12 . The composition of claim 1 , wherein the Saccharomyces cerevisiae S288C EV1-Peptide is encapsulated in a vegan capsule engineered for delayed release in the small intestine.

13 . The composition of claim 1 , wherein the Saccharomyces cerevisiae S288C EV1-Peptide is present in a dry powder form.

14 . The composition of claim 1 , wherein the composition is a dietary supplement.

15 . A method of reducing appetite in a human subject, comprising: administering the composition of claim 1 to a human in need thereof.

16 . A method of reducing appetite in a human subject, comprising: administering the composition of claim 1 to a human in need thereof in an amount containing about 100 mg to about 600 mg of Saccharomyces cerevisiae S288C EV1-Peptide.

17 . A method of reducing appetite in a human subject, comprising: administering the composition of claim 1 to a human in need thereof in an amount containing about 300 mg of Saccharomyces cerevisiae S288C EV1-Peptide.

18 . A method of reducing appetite in a human subject, comprising: administering the composition of claim 1 to a human in need thereof in an amount containing about 500 mcg to about 3000 mcg of EV1-Peptide.

19 . A method of reducing appetite in a human subject, comprising: administering the composition of claim 1 to a human in need thereof in an amount containing about 800 to about 2000 mcg of EV1-Peptide.